Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12160052 | 0.85 | HDAC6 (0.40) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL8606993 | 0.82 | HDAC6 (0.38) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL4659197 | 0.82 | HDAC6 (0.36) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL2435231 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL7747137 | 0.79 | HDAC6 (0.36) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL23425907 | 0.79 | HDAC6 (0.41) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL5033844 | 0.79 | HDAC6 (0.37) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL24271052 | 0.79 | HDAC6 (0.33) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL27505816 | 0.78 | MGAM (0.38) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL1696194 | 0.78 | HDAC6 (0.35) | HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| CN-103342680-A | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMA CO LTD | 2013-10-09 | — | — | CN | disclosed |
| CN-103342679-A | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMA CO LTD | 2013-10-09 | — | — | CN | disclosed |
| CN-1964975-B | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-11-30 | — | — | CN | disclosed |
| CN-101687805-A | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMA CO LTD | 2010-03-31 | — | — | CN | disclosed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
| CN-1964975-A | HIV integrase inhibitors | MERCK & CO INC (US) | 2007-05-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287394-A1 | Hiv Integrase Inhibitors | DHPS, DPYD, TYMP | HDAC6 4199/4885HDAC1 568/4885HDAC2 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.